Evidence map›Paper›PMID 40913820›Full record

ArticleImmunobiology2025

Stability testing of HPCs and MNCs from apheresis products.

Jinxia Ma, Lipei Shao, Tatyana Fuksenko, Hui Liu, Chunjie Jiang, Yihua Cai, Yong Soo Kim, Kathryn Martin, Larry Moses, Nan Zhang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jinxia MaCenter for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, NIH Clinical Center, Bethesda, MD 20892, USA.
Lipei ShaoCenter for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, NIH Clinical Center, Bethesda, MD 20892, USA.
Tatyana FuksenkoCenter for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, NIH Clinical Center, Bethesda, MD 20892, USA.
Hui LiuCenter for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, NIH Clinical Center, Bethesda, MD 20892, USA.
Chunjie JiangCenter for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, NIH Clinical Center, Bethesda, MD 20892, USA.
Yihua CaiCenter for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, NIH Clinical Center, Bethesda, MD 20892, USA.
Yong Soo KimCenter for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, NIH Clinical Center, Bethesda, MD 20892, USA.
Kathryn MartinCenter for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, NIH Clinical Center, Bethesda, MD 20892, USA.
Larry MosesCenter for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, NIH Clinical Center, Bethesda, MD 20892, USA.
Nan ZhangCenter for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, NIH Clinical Center, Bethesda, MD 20892, USA.
Anh DinhCenter for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, NIH Clinical Center, Bethesda, MD 20892, USA.
Robert P SomervilleCenter for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, NIH Clinical Center, Bethesda, MD 20892, USA.
David F StroncekCenter for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, NIH Clinical Center, Bethesda, MD 20892, USA.
Ping JinCenter for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, NIH Clinical Center, Bethesda, MD 20892, USA. Electronic address: pjin@mail.cc.nih.gov.

Funding

Intramural NIH HHS Z99 CL999999
6 · The paper itself

Abstract

backgroundHematopoietic progenitor cells (HPCs) and mononuclear cells (MNCs) are critical components of cell-based therapies, including bone marrow transplantation and regenerative treatments. Evaluation of the characteristics of these products during collection, storage, and transport is essential for maintaining cell viability and functionality. In this study, we evaluated the functional and molecular stability of samples collected for the evaluation of fresh HPC and MNC products. The samples stored at 4 °C for up to 4 days and were evaluated using white blood cell (WBC) counts, flow cytometry, and bulk RNA sequencing (RNA-seq) across five time points.

methodsHPC samples from seven products (June-December 2022) and MNC samples from six products (October 2022-August 2023) were analyzed on days 0 through 4 after collection. WBC counts were measured, and viability was assessed using 7-AAD staining and flow cytometry. HPC samples were stained with antibodies against CD34, CD3, CD19, CD56, CD14, CD16, CD15, and CD45, while MNC samples were stained with antibodies directed to CD3, CD4, CD8, CD19, CD56, CD14, CD16, CD15, and CD45. Total RNA was isolated from each sample and subjected to bulk RNA-seq to assess transcriptomic changes during storage.

resultsWhile WBC counts varied between products, no significant differences were observed across time points within individual products. Flow cytometry markers remained relatively stable over time in both HPC and MNC samples, although greater variability was observed in HPCs. A modest decrease in lymphocyte percentages was noted at later time points, primarily driven by a reduction in CD3+ cells; however, these changes were not statistically significant. Cell viability declined significantly over time within individual products and showed inter-product variability. RNA-seq analysis revealed stable gene expression profiles in MNC samples across all time points. In contrast, HPC samples exhibited notable transcriptomic changes as early as day 1 of storage at 4 °C, indicating greater molecular instability.

conclusionWBC counts and flow cytometry markers remain stable for up to 3 days in samples collected from fresh HPC and MNC products when stored at 4 °C, although cell viability progressively declines. However, RNA-seq data reveal early transcriptomic changes in HPC samples, suggesting that immediate evaluation of these samples is critical to preserve their molecular integrity and functionality. These findings support the feasibility of delayed phenotypic analysis but emphasize the need for prompt molecular assays in HPC-based applications.

Indexed as

Blood Component RemovalHematopoietic Stem CellsLeukocytes, MononuclearAntigens, CDBiomarkersCell SurvivalFlow CytometryHumansLeukocyte CountAntigens, CDBiomarkersApheresis productsImmunophenotypeQuality controlStability

Identifiers

PMID40913820
PMCPMC12429779

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.